Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Edward Garon, MD, Associate Professor of Medicine, Geffen School of Medicine at UCLA, discuss lung cancer highlights from ASCO 2019.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss HCC highlights from ASCO 2019.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Scott Kopetz, MD, PhD, FACP, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson, provide CRC clinical update post World GI '19.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss ovarian cancer clinical updates from ESMO 19

A round-up of some of the notable pivotal trial data presented in Barcelona that expanded treatment options for patients, including studies in triple negative breast cancer (KEYNOTE-522), advanced NSCLC (CheckMate 027), EGFR-mutation positive NSCLC (FLAURA), and metastatic bladder cancer (IMvigor130).

At ESMO 2019, the biggest clinical news was three late-stage standout studies in first-line advanced ovarian cancer with the PARP inhibitors niraparib, olaparib, and veliparib. Data from the three trials, PRIMA, PAOLA-1, and VELIA respectively, demonstrated improved survival for almost all patient subtypes without significantly impacting quality of life.

In another exclusive report, OnPoint Oncology provides an analysis of the largest non-Blue Commercial plans compared to the gold standard, Medicare. The analysis looks at the data on denial rates, days from service to claims filing (Days to File), and days from service to positive adjudication (Days to Pay) comparing the most expensive physician-administe...

At Flatiron’s OncoCloud ’19 meeting, OBR sat down with three leading OneOncology providers to talk about how implementing data-connectivity through cloud-based oncology software like OncoEMR is changing the face of community oncology, delivery models and the patient experience.